News

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.

The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."

“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."

“The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”

“RASMT associated with adverse phenotypic features were concluded to be an independent predictor of inferior overall survival and were associated with a higher cumulative incidence of leukemic transformation."

Targeted Oncology reviews trending news online for the week of June 19, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

“Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result."

During a debate made available as part of the 2020 National Comprehensive Cancer Network Virtual Annual Conference, Deborah Stephens, DO, and Mazyar Shadman, MD, MPH, discussed the most optimal frontline therapy for chronic lymphocytic leukemia.

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.

In an interview with  Targeted Oncology,  Marcia Brose, MD, PhD, discussed the importance of conducting genetic testing on all patients with metastatic solid tumors following the exciting data on larotrectinib.

Fruquitinib was granted Fast Track Designation for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, as well as anti-EGFR therapy for RAS wild-type tumors

“Community-based clinical trials come with many benefits. They enable patients to be matched with potentially life-saving research while staying within the comfort and familiarity of their local oncologist’s office.”

"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."

FoundationOne CDx has been approved by the FDA as a companion diagnostic for pembrolizumab to identify patients with tumor mutational burden–high solid tumors who would benefit from this therapy.

“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."

In an interview with Targeted Oncology, Suresh Ramalingam, MD, FASCO, discussed the findings from the CheckMate 227 study that support the FDA’s approval of the combination of nivolumab and ipilimumab in patients with advanced NSCLC.

A liposomal irinotecan combination was granted FDA Fast Track designation for the treatment of untreated and unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.

“While the trial is still ongoing, we are encouraged by the efficacy we are seeing thus far in patients with relapsed/refractory AML, particularly the durability of response observed in some patients."

"KEYNOTE-158 has confirmed clinical activity of pembrolizumab in tumors harboring a TMB ≥10 across a variety of solid tumors including anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small cell lung, thyroid, and vulvar cancers."

In an interview with Targeted Oncology, Lucy Gilbert, MD, MSc, discussed the interim findings for mirvetuximab in combination with bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

In an interview with Targeted Oncology, Andrew L. Coveler, MD, discussed the phase 1 trial study of SEA-CD40 combined with a chemotherapy regimen, which he recently presented during the ASCO Virtual Scientific Program.

The FDA expanded the approval of gemtuzumab ozogamicin to include an indication for the treatment of newly diagnosed pediatric patients with CD33-positive acute myeloid leukemia, which includes patients as young as 1 month old.

"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "

“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."

A pooled analysis of phase 3 clinical trials in advanced renal cell carcinoma showed that combination immunotherapy can reduce toxicity compared with sunitinib.

“These interim results from the PROTECTIVE-2 Phase 3 study, which compares the Plinabulin-Neulasta combination to Neulasta alone, have the potential to be clinically meaningful for cancer patients receiving chemotherapy."

“Today’s approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Merck’s mission to help reduce the number of men and women affected by certain HPV-related cancers.”